<DOC>
	<DOCNO>NCT02653131</DOCNO>
	<brief_summary>The inhibition Dipeptidyl peptidase-4 increase concentration glucagone-like peptide 1 2 , increase latter increase absorptive capacity intestine .</brief_summary>
	<brief_title>The Use DPP-4 Inhibitors Short Bowel Syndrome</brief_title>
	<detailed_description>The effective ( extend drug ) short bowel syndrome Glucacone-like peptide 4 . Its price , however , high really change treatment strategy intestinal failure . The Dipeptidyl peptidase-4 inhibitor , drug commonly use treatment diabetes mellitus type II , increase concentration glucagone-like peptide 1 2 , increase latter increase absorptive capacity intestine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>patient receive home parenteral nutrition ( HPN ) short bowel syndrome least 12 month stable metabolic status benign disease HPN &lt; 12 month metabolically unstable cancer reason intestinal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Short bowel syndrome</keyword>
</DOC>